← Evidence map

ArticleHaematologica2025

Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on "Targeted anti-cancer agents and risk of venous thromboembolism".

Catherine Duane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2025

this papercites it

Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on "Targeted anti-cancer agents and risk of venous thromboembolism". | OpenQuestion